提醒成功
微信/QQ登錄
搜索
首頁
| 產品規范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00050 |
| Application | Flow cytometry, animal model study |
| Aliases | Anti-KDR Human Monoclonal Antibody, Ramucirumab Research Grade, Ramucirumab RUO |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human VEGFR2 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
What is ramucirumab biosimilar research grade? Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis. Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC. |
Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody B00050
產品中心
Product技術服務
service客戶留言
message